

Original Research Article

Cystatin C- an early diagnostic biomarker of diabetic kidney disease

ABSTRACT

Aims: This study was aimed to find out better biomarker between serum Creatinine and serum cystatin C, which will help in early diagnosis of diabetic kidney disease.

Study design: Cross-sectional study.

Place and Duration of Study: Department of Biochemistry, LTM Medical College, Sion, Mumbai, between January 2014 to November 2014.

Methodology: Diagnosed patients of type 2 diabetes mellitus were evaluated based on detailed history, clinical examination and laboratory investigations. Patients having frank proteinuria were excluded. Patients without proteinuria were tested for microalbuminuria. In study group, we included 50 patients having microalbuminuria and in control group, 50 patients without microalbuminuria. Serum Creatinine and serum cystatin C were estimated. Results were analysed by unpaired t-test & P-value was determined.

Results: Serum cystatin C was found to be increased in microalbuminuria patients as compared with controls and difference was statistically significant ($P = 0.000$). We also found increased levels of serum creatinine which was not significant ($P = 0.11$).

Conclusion: Diabetes has become the most common single cause of end stage renal disease (ESRD) worldwide. The results of this study suggest that serum cystatin C measurement is a useful, practical, non-invasive tool for the evaluation of renal involvement in the course of diabetes, as serum creatinine values are affected by many factors like age, sex, muscle mass, diet and offers a hope that Diabetic kidney disease can be well prevented with appropriate interventions.

Keywords: Diabetic kidney disease, microalbuminuria, serum cystatin C, serum creatinine.

1. INTRODUCTION

Diabetes is one of the most challenging health problems of the 21st century. The prevalence of diabetes is increasing globally. Type 2 DM constitutes about 85% to 95% of total diabetic cases in developed countries and accounts for higher percentage in developing countries.¹ Moreover, type 2 DM is a significant cause of premature mortality and morbidity related to cardiovascular disease, macrovascular complications and microvascular complications in older adults.²⁻⁴

Diabetes leads to various chronic complications which can be divided into vascular and nonvascular complications. Diabetes has become the most common single cause of end

stage renal disease (ESRD) worldwide⁵. About 20-30% of patients with type 1 or type 2 diabetes mellitus develop evidence of nephropathy, but in type 2 diabetes, a considerably smaller fraction of these progresses to ESRD. However, because of much higher prevalence of type 2 diabetes mellitus, these patients constitute over half of patients with nephropathy needing dialysis⁶. The diabetic kidney disease progresses from appearance of low but abnormal levels of ($\geq 30\text{mg}$ to 299 mg/day) albumin in urine (stage of microalbuminuria) to stage of macroalbuminuria / clinical albuminuria ($\geq 300\text{mg/day}$) to ESRD. Progress from microalbuminuria to macroalbuminuria usually takes 10-15 years. It remains underdiagnosed in the diabetic population. Type 2 DM may be present for decade before diagnosis and patient may present with complications at the time of diagnosis. So early recognition of diabetic kidney disease by health care professionals is vital for proper management.

Although serum creatinine has been widely used as a marker, but it is not able to pick up early decreased renal function. Therefore, various plasma low molecular weight proteins have been suggested as valuable markers of decreased renal function in place of serum creatinine.

Although number of investigations are available, many of these are not done in public hospitals, thereby missing diagnosis of diabetic kidney disease at early stage. This could be due to non availability of resources, manpower or funds. This current study is aimed to evaluate the levels of serum Creatinine and serum cystatin C in type 2 diabetic patients.

2. MATERIAL AND METHODS

The study was conducted in LTM Medical College, Sion, Mumbai after the approval from ethics committee. The diagnosed patients of type 2 diabetes mellitus attending medicine OPD at LTM Medical College, Sion, Mumbai were enrolled for the study. On fulfilling the criteria, the study design was explained to the patients with the help of information sheet. Then the written consent was taken.

24 hrs urine sample was tested for proteinuria by using TCA method. Patients having frank proteinuria were excluded. Patients negative for frank proteinuria were further tested for microalbuminuria. In study group, we included 50 patients having microalbuminuria and in control group, 50 patients without microalbuminuria.

Urine albumin by immunoturbidimetric method^{7,8}, Serum creatinine by modified Jaffe's method⁹, Serum cystatin C by immunoturbidimetry¹⁰ were estimated. Patients having frank proteinuria, any known renal disease, taking any medications affecting renal functions, patients with urinary tract infections or hematuria or febrile illness, patients having paraplegia, muscle wasting disease or any neuromuscular disorders were excluded.

Statistical Analysis :

For each parameter to be studied, mean and standard deviation was calculated to estimate the significance. The difference between the groups was measured by Students Unpaired 't' test. P Value less than 0.01 considered as statistically significant.

3. RESULTS AND DISCUSSION

Table shows a non-significantly ($p = 0.11$) increased levels of Serum creatinine in the diabetic kidney disease patients ($0.77 \pm 0.13\text{ mg/dl}$) as compared to the controls ($0.74 \pm 0.08\text{ mg/dl}$).


70 There was a significant ($p < 0.01$) increase in levels of Serum Cystatin C in diabetic
71 kidney disease patients (1.61 ± 0.27 mg/L) as compared to the controls (0.85 ± 0.12 mg/L).

72

73 **Comparison of Serum Creatinine and Serum Cystatin C:**

Parameter	Controls(n= 50)	Cases(n= 50)	P value
Serum Creatinine(mg/dl)	0.74 ± 0.08	0.77 ± 0.13	.11
Serum cystatin C(mg/L)	0.85 ± 0.12	1.61 ± 0.27	.000


74



75

76 **Fig.1. Comparison of Serum creatinine between Control and Study group**

77



78 **Fig. 2. Comparison of Serum Cystatin C between Control and Study group**

79

80 **DISCUSSION:**

81 Overt diabetic nephropathy classically begins with dipstick-positive proteinuria
82 (urinary albumin excretion > 300 mg/24 h) followed or accompanied by the development of
83 hypertension and/or falling glomerular filtration rate^{11,12}. At this stage, renal lesions of

84 diabetes, including diffuse mesangial expansion and consequent loss of filtration surface,
85 arteriolar hyalinosis, and global glomerular sclerosis are advanced, and the progression
86 toward endstage renal disease may be slowed but not reversed¹³. Overt nephropathy is
87 preceded by a variable period, which has been called 'incipient nephropathy'¹².

88 This phase of the natural history of diabetic nephropathy has been defined as an
89 elevation of urinary albumin excretion to levels considered predictive of nephropathy risk but
90 less than the levels that usually give positive dipstick results (30-300 mg/24 hrs). The lower
91 limit of urinary albumin excretion, which is said to be predictive of the later development of
92 overt nephropathy, has been variably reported as around 30 mg/24 h¹⁴⁻¹⁷.

93 Some patients with microalbuminuria may also have hypertension or a falling GFR,
94 and this group of patients with microalbuminuria more regularly have advanced glomerular
95 lesions¹⁸. Before these stages are many silent years during which no clinical or laboratory
96 parameter is indicative of underlying renal structural lesions or of eventual nephropathy risk.
97 These years are characterized by urinary albumin excretion and normal or elevated GFR.
98 Glomerular structure during the silent period can range from normal to lesions bordering on
99 those of overt nephropathy.

100 Microalbuminuria has been shown by several groups of investigators to indicate a
101 high risk for the later development of overt nephropathy. Studies have shown that urinary
102 albumin excretion in the range agreed by most investigators to be associated with increased
103 nephropathy risk is frequently associated with reduced GFR and more severe diabetic
104 glomerular pathology. Thus, it is likely that microalbuminuria predicts the later development
105 of overt diabetic nephropathy by serving as a functional indicator of underlying renal
106 structural changes.

107 Several studies have shown that slight increases in albuminuria (microalbuminuria)
108 precede the development of clinical diabetic nephropathy by several years¹⁹. The concept of
109 a prognostic role for microalbuminuria has been extended to suggest that normoalbuminuria
110 ensures no reduction of renal function²⁰. Based on this, we divided type 2 diabetic patients in
111 2 groups depending on their different degrees of kidney damage (normoalbuminuria and
112 microalbuminuria).

113 In this study, we aimed at evaluating the different biomarkers for early diagnosis of
114 diabetic kidney disease like S. Creatinine and S. Cystatin C in a small cohort of patients with
115 type 2 diabetes by categorizing them into 2 groups based on their urine albumin status.
116 Our data agrees with the studies carried out by Yun Kyung Jeon et al²¹. The difference was
117 insignificant for serum creatinine, though the mean value was slightly increased in study
118 group.

119 Out of 50 patients of study group, the increase in serum cystatin C was observed in
120 47 patients and maximum value was 2.05 mg/L in study group. Our results are in
121 accordance with the studies carried out by Bruce A. Perkins et al²², Min Zhang et al²³, Laura
122 Pucci et al²⁴, Jan Kyhse-Andersen et al²⁵ and Radovan Hojs et al²⁶.
123

124 The routine classical evaluation of diabetic kidney disease includes appearance of
125 microalbuminuria, decreased creatinine clearance and increased serum creatinine. Many
126 clinicians use serum creatinine in evaluating such patients. However, serum creatinine
127 depends on creatinine production, extrarenal elimination and tubular handling²⁷.

128 Moreover, tubular involvement may precede glomerular involvement because
129 several tubular proteins and enzymes are detectable even before the appearance of
130 microalbuminuria and a rise in serum creatinine. Therefore, other biomarkers for estimation
131 of renal function have been searched for and one of them was serum cystatin C²⁸. Our study

results confirmed that cystatin C could be one of the additional tubular factors which represents kidney state of diabetic patients.

It was thought that increment in serum Cystatin C was probably due to the tubular phase before glomerular manifestation. This suggests that the serum cystatin C levels are related to subclinical tubular impairment and can be an earlier measurable markers of renal involvement²⁸. Our results indicate that serum cystatin C is a novel and reliable marker of GFR. Zahran et al reviewed a number of studies to compare the diagnostic accuracy of serum cystatin C levels and serum creatinine levels in many clinical situations, including transplant patients, patients with native kidney disease, adults with native kidney disease, and pediatric patients with native kidney disease. They found that serum Cystatin C was superior to serum creatinine²⁹.

Until now, traditional measures for assessing renal function such as measuring serum creatinine have been widely used, although they have some limitations. Here, we evaluated the diagnostic efficacy and accuracy of using serum cystatin C levels and compared these results to those obtained using traditional renal function indicator such as serum creatinine. Our study found that the diagnostic accuracy of serum cystatin C levels was superior to that of serum creatinine.

Although serum creatinine has become the most popularly used serum marker of renal function, serum creatinine may be unreliable because it is frequently affected by muscle mass, age, gender, aberrant renal tubular regulation and methodology of determining serum creatinine level. Using serum cystatin C levels has some advantages over serum creatinine, in that serum Cystatin C levels are independent of age, gender, muscle mass, diet, inflammatory status and renal tubular secretion³⁰. So serum cystatin C can be considered to be an ideal indicator of GFR.

4. CONCLUSION

In conclusion, the results of this study suggest that serum cystatin C measurement is a useful, practical, non-invasive tool for the evaluation of renal involvement in the course of diabetes. Though urine albumin to creatinine ratio was statistically significant, it has been reported that a decline in the renal function of patients with diabetes is not always accompanied by an increased urine albumin to creatinine ratio, as both albumin and creatinine values are affected by many things like age, sex, muscle mass, diet, etc. Further investigations with a larger sample size and a prospective design are required to confirm the potential application of cystatin C as a useful biomarker for the early detection of diabetic kidney disease.

Diabetic kidney disease is the leading cause of chronic kidney disease and end stage renal disease. Early recognition is vital for further management. Serum Cystatin C can be used as an early independent marker of diabetic kidney disease, as routine biochemical parameters like BUN & serum creatinine fail to recognize early diabetic kidney disease.

REFERENCES

1. IDF Diabetes Atlas, International Diabetes Federation, 2009, 4th edition.
2. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ: Glycemic control, complications, and death in older diabetic patients the diabetes and aging study. *Diabetes Care* 2011, 34(6):1329–1336.
3. De Boer IH, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, et al: Cystatin C, albuminuria, and mortality among older adults with diabetes. *Diabetes Care* 2009, 32(10):1833–1838.
4. Andrew Moran, Walter Palmas, Lesley Field, Jyoti Bhattarai, Joseph E. Schwartz, Ruth, et al. Cardiovascular Autonomic Neuropathy Is Associated With

- 183 Microalbuminuria in Older Patients With Type 2 Diabetes . Diabetes Care April
184 2004 27:972-977.
- 185 5. Powers A. C. Diabetes mellitus. Fauci As, Kasper DL, Braunwald E, Hauser SL,
186 Longo DL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal
187 medicine 18th edition, chapter 344, 2968-3003.
- 188 6. American Diabetes Association. Diagnosis and classification of diabetes
189 mellitus. Diabetes Care 2004;27(Suppl. 1):S5–S10.
- 190 7. Mount J, J. Clin. Pathology,1986, 22, 12
- 191 8. Schmidt A et al, Diabetic Medicine, vol.5, 1988,126-134
- 192 9. Henry,R.J.,et al.“Clinical Chemistry- Principles and Techniques” Harper &
193 Row, II Ed.1974.
- 194 10. Filler G, Bokenkamp A, Hofmann W. Cystatin C as a marker of GFR-history,
195 indication and future research. Clin Biochem 2005;38:1-8.
- 196 11. Tuttle KR, Stein JH, DeFronzo RA: The natural history of diabetic nephropathy.
197 Semin Nephrol 10: 184-93, 1990
- 198 12. Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease:
199 with emphasis on the stage of incipient diabetic nephropathy. Diabetes 32(Suppl. 2)
200 1983, 64 -78
- 201 13. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz F: Structural-
202 functional relationships in diabetic nephropathy. J Clin Invest, 1984, 74: 1143-55
- 203 14. Mogensen C, Christensen C: Predicting diabetic nephropathy in insulin-dependent
204 patients. N Engl J Med, 1984, 311: 89-93
- 205 15. Viberti G, Jarrett R, Mahmud U, Hill R, Argyropoulos A, Keen H: Microalbuminuria
206 as a predictor of clinical nephropathy in insulin dependent diabetes mellitus.
207 Lancet,1982,1: 1430-32
- 208 16. Parving H-H, Oxenboll B, Svendsen P, Christiansen JS, Andersen A: Early detection
209 of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary
210 albumin excretion. Acta Endocr 1982/ no/100:550-55
- 211 17. Mathiesen E, Oxenboll B, Johansen K, Svendsen P, Deckert T: Incipient
212 nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia,1984, 26:406-10
- 213 18. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM: Glomerular lesions and
214 urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med
215 320:966-70
- 216 19. Mogensen CE, Hansen KW, Sommer S, Klebe J, et al: Microalbuminuria: studies in
217 diabetes, essential hypertension, and renal diseases as compared with the
218 background population. Adv Nephrol, 1991, 20:191-228
- 219 20. Hansen KW, Mau Pedersen M, Christensen CK, Schmitz A, Christiansen JS,
220 Mogensen CE: Normoalbuminuria ensures no reduction of renal function in type I
221 (insulin-dependent) diabetic patients. J Intern Med, 1992, 232:161-167
- 222 21. Yun Kyung Jeon, Mi Ra Kim, Jung Eun Huh, Ji Young Mok et al Cystatin C as an
223 Early Biomarker of Nephropathy in Patients with Type 2 Diabetes J Korean Med Sci
224 2011; 26: 258-263
- 225 22. Bruce A. Perkins,Robert G. Nelson,Betsy E.P. Ostrander et al Detection of Renal
226 Function Decline in Patients with Diabetes and Normal or Elevated GFR by Serial
227 Measurements of Serum Cystatin C Concentration: Results of a 4-Year Follow-Up
228 Study J Am Soc Nephrol 16: 1404–1412, 2005.
- 229 23. Min Zhang, Xueying Cao, Guangyan Cai et al Clinical evaluation of serum cystatin C
230 and creatinine in patients with chronic kidney disease: A meta-analysis Journal of
231 International Medical Research 41(4) 944–955
- 232 24. Laura Pucci, Stefano Triscornia, Daniela Lucchesi et al Cystatin C and Estimates of
233 Renal Function: Searching for a Better Measure of Kidney Function in Diabetic
234 Patients Clinical Chemistry 2007,53:3 480–488

- 235 25. Jan Kyhse-Andersen, Camilla Schmidt, Gunnar Nordin et al Serum Cystatin C,
236 Determined by a Rapid, Automated Particle-Enhanced Turbidimetric Method, Is a
237 Better Marker than Serum Creatinine for Glomerular Filtration Rate CLIN. CHEM.
238 1994, 40/10, 1921-1926
- 239 26. Radovan Hojs, Sebastjan Bevc , Robert Ekart , Maksimiljan Gorenjak and Ludvik
240 Puklavec Serum cystatin C as an endogenous marker of renal function in patients
241 with mild to moderate impairment of kidney function Nephrol Dial Transplant, 2006,
242 21: 1855–1862
- 243 27. Stevens L A, Levey A S. Measurement of kidney function. Med Clin North Am 2005;
244 89:457-73.
- 245 28. Choe JY, Park SH, Kim SK. Serum Cystatin C is a potential endogenous marker for
246 the estimation of renal function in male gout patients with renal impairment. J
247 Korean Med Sci 2010;25:42-8.
- 248 29. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate
249 glomerular filtration rate? A literature review. Am J Nephrol 2007; 27: 197–205
- 250 30. Mojiminiyi OA and Abdella N. Evaluation of cystatin C and beta-2 microglobulin as
251 markers of renal function in patients with type 2 diabetes mellitus. J Diabetes
252 Complications 2003; 17: 160–168.